MediciNova Initiates Phase II Clinical Trial for MN-305, a Novel
PrimeZone - HT1A receptor under development both for the treatment of insomnia as well as for anxiety disorders such as Generalized Anxiety Individuals suffering from insomnia exhibit at least one of the following symptoms: - difficulty falling asleep (sleep
Source: www.primezone.com
Click here for more information about articles directory
<< Home